Search Results

Cyclica Inc. and the National Research and Innovation Agency announce a partnership leveraging Cyclica’s AI-enabled drug discovery platform to drive innovation within Uruguay’s biotech ecosystem.

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed agreements to acquire two companies in the AI-enabled drug discovery space: Cyclica and Valence.

Cyclica Inc. (“Cyclica”), a neo-biotech that is unlocking the protein universe to discover the medicines of tomorrow, and SK Chemicals Co., Ltd. (“SK Chemicals”), a global leader in total healthcare providing diagnostic, therapeutic and prophylactic solutions, today announced an AI-driven drug discovery and development partnership to develop therapies across a range of disease areas.

Champions Oncology, Inc. and Cyclica Inc. announced today a therapeutic development partnership.

Cyclica receives a grant from the Bill & Melinda Gates Foundation to apply its AI-enabled drug discovery platform to discover new therapeutic options for multiple low-data biological targets with the goal of expanding the range of accessible non-hormonal contraceptive choices for women in developing countries.

Nurosene Health Inc. (“Nurosene” or the “Company”) (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), is partnering, via its wholly owned subsidiary NetraMark Corp. (“NetraMark”), with Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline.

Cyclica Inc., and Arctoris Ltd. have agreed to expand their partnership to progress drug discovery programs for novel neurodegenerative targets with a focus on Alzheimer’s disease.

Cyclica Inc. (“Cyclica”), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, today launches Perturba Therapeutics Inc. (“Perturba”), a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research.

Cyclica Inc. welcomes drug discovery veteran Michael (Mike) Palovich as Chief Science Officer, Head of Drug Discovery.

Cyclica and IMPACT Therapeutics announce today that they have entered to a collaboration agreement on IMPACT Therapeutics’ differentiated targeted anti-cancer drug development.